Charles Schwab Investment Management Inc. Purchases 7,165 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Charles Schwab Investment Management Inc. boosted its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC) by 1.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 604,397 shares of the biotechnology company’s stock after acquiring an additional 7,165 shares during the period. Charles Schwab Investment Management Inc. owned 0.95% of Blueprint Medicines worth $52,716,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in BPMC. Quarry LP bought a new stake in Blueprint Medicines during the 3rd quarter worth approximately $32,000. R Squared Ltd bought a new stake in Blueprint Medicines during the 4th quarter worth approximately $51,000. Covestor Ltd grew its holdings in Blueprint Medicines by 206.7% during the 3rd quarter. Covestor Ltd now owns 598 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 403 shares in the last quarter. Asset Management One Co. Ltd. purchased a new stake in Blueprint Medicines during the 4th quarter valued at approximately $88,000. Finally, Van ECK Associates Corp grew its holdings in Blueprint Medicines by 48.2% during the 4th quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock valued at $97,000 after buying an additional 363 shares in the last quarter.

Blueprint Medicines Stock Performance

BPMC opened at $89.84 on Friday. Blueprint Medicines Co. has a 52-week low of $80.68 and a 52-week high of $121.90. The firm’s 50-day moving average price is $99.46 and its 200-day moving average price is $94.09. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. The company has a market cap of $5.74 billion, a P/E ratio of -83.18 and a beta of 0.58.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.68) by ($0.11). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. As a group, equities analysts anticipate that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.

Wall Street Analyst Weigh In

BPMC has been the subject of a number of research analyst reports. Scotiabank initiated coverage on shares of Blueprint Medicines in a report on Friday, March 7th. They set a “sector outperform” rating and a $150.00 price objective for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $133.00 price objective on shares of Blueprint Medicines in a report on Thursday, February 13th. Piper Sandler increased their price objective on shares of Blueprint Medicines from $109.00 to $119.00 and gave the company a “neutral” rating in a report on Monday, January 27th. JPMorgan Chase & Co. increased their price objective on shares of Blueprint Medicines from $126.00 to $129.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Finally, Stephens reissued an “overweight” rating and issued a $140.00 target price on shares of Blueprint Medicines in a report on Thursday, January 2nd. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $125.21.

Insider Buying and Selling at Blueprint Medicines

In other Blueprint Medicines news, insider Ariel Hurley sold 2,250 shares of the firm’s stock in a transaction on Monday, January 13th. The stock was sold at an average price of $100.00, for a total value of $225,000.00. Following the transaction, the insider now owns 14,967 shares in the company, valued at approximately $1,496,700. This trade represents a 13.07 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Kate Haviland sold 1,446 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $110.24, for a total value of $159,407.04. Following the completion of the transaction, the chief executive officer now owns 149,378 shares in the company, valued at $16,467,430.72. The trade was a 0.96 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 46,608 shares of company stock worth $4,668,161. Corporate insiders own 4.21% of the company’s stock.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.